These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22028789)

  • 1. Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test.
    Langford-Smith A; Langford-Smith KJ; Jones SA; Wynn RF; Wraith JE; Wilkinson FL; Bigger BW
    PLoS One; 2011; 6(10):e25717. PubMed ID: 22028789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice.
    Lau AA; Crawley AC; Hopwood JJ; Hemsley KM
    Behav Brain Res; 2008 Aug; 191(1):130-6. PubMed ID: 18453006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).
    Hemsley KM; Hopwood JJ
    Behav Brain Res; 2005 Mar; 158(2):191-9. PubMed ID: 15698885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPS-IIIA mice acquire autistic behaviours with age.
    Lau AA; Tamang SJ; Hemsley KM
    J Inherit Metab Dis; 2018 Jul; 41(4):669-677. PubMed ID: 29520737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments.
    Langford-Smith A; Malinowska M; Langford-Smith KJ; Wegrzyn G; Jones S; Wynn R; Wraith JE; Wilkinson FL; Bigger BW
    Genes Brain Behav; 2011 Aug; 10(6):673-82. PubMed ID: 21635693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucopolysaccharidosis (MPS IIIA) mice have increased lung compliance and airway resistance, decreased diaphragm strength, and no change in alveolar structure.
    Paget TL; Larcombe AN; Pinniger GJ; Tsioutsias I; Schneider JP; Parkinson-Lawrence EJ; Orgeig S
    Am J Physiol Lung Cell Mol Physiol; 2024 Jun; 326(6):L713-L726. PubMed ID: 38469649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA.
    Pericleous K; McIntyre C; Fuller M
    Mol Genet Metab Rep; 2023 Sep; 36():100985. PubMed ID: 37332488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
    Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
    Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
    Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
    Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking α-synuclein.
    Soe K; Beard H; Neumann D; Trim PJ; Duplock S; Snel MF; Hopwood JJ; Hemsley KM
    Neuropathol Appl Neurobiol; 2019 Dec; 45(7):715-731. PubMed ID: 30907009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
    Perkins KJ; Muller V; Weber B; Hopwood JJ
    Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
    Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
    Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease.
    Mandolfo O; Parker H; Aguado È; Ishikawa Learmonth Y; Liao AY; O'Leary C; Ellison S; Forte G; Taylor J; Wood S; Searle R; Holley RJ; Boutin H; Bigger BW
    EMBO Mol Med; 2024 Jul; 16(7):1579-1602. PubMed ID: 38890537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.
    King B; Setford ML; Hassiotis S; Trim PJ; Duplock S; Tucker JN; Hattersley K; Snel MF; Hopwood JJ; Hemsley KM
    Exp Neurol; 2016 Apr; 278():11-21. PubMed ID: 26626972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.